DLB, Dolby

Dolby Laboratories (DLB) to Release Quarterly Earnings on Wednesday
Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes on Wednesday, January 29th. Analysts expect Dolby Laboratories to post earnings of $1.
Compared to Estimates, Dolby Laboratories (DLB) Q1 Earnings: A Look at Key Metrics
Dolby Laboratories (DLB) reported $357 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 13.1%. EPS of $1.14 for the same period compares to $1.01 a year ago.
Dolby's Q1 Earnings & Revenues Surpass Estimates, Increase Y/Y
DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.
Dolby Laboratories (DLB) Tops Q1 Earnings and Revenue Estimates
Dolby Laboratories (DLB) delivered earnings and revenue surprises of 6.54% and 3.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Dolby Laboratories, Inc. (NYSE:DLB) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Ladies and gentlemen, thank you for standing by.
Dolby Laboratories Earnings Review: Q1 Summary
Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same period last year. In the previous quarter, the company beat on EPS by $0.11, resulting in a 16.0% increase change in the share price the following day.
Dolby Laboratories: Fiscal Q1 Earnings Snapshot
The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.07 per share. The creator and licensor of audio, video and voice technologies posted revenue of $357 million in the period,
Earnings call transcript: Dolby Labs beats Q1 2025 EPS forecast, stock rises
Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations and witnessing a positive market reaction. The company achieved earnings per share (EPS) of $1.
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from ...
news.stocktradersdaily6d
How the (DLB) price action is used to our Advantage
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Here's Why We Think Dolby Laboratories (NYSE:DLB) Is Well Worth Watching
The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus ...
CervoMed provides update on neflamapimod DLB program
CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation ...
stocknews13d
Is Dolby Laboratories a Sound Investment in Audio Technology?
Audio technology is evolving at a rapid pace with growing investments in cutting-edge technologies and innovations. Dolby ...
Knowridge5d
This test could achieve early diagnosis of dementia with Lewy bodies
A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies ...
Dolby reports Q1 adjusted EPS $1.14, consensus 98c
Reports Q1 revenue $357M, consensus $345.44M. “We are off to a strong start for FY25,” said Kevin Yeaman, President and CEO, Dolby (DLB) ...